PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10575977	
	Filing Date		2007-05-02	
	First Named Inventor Haijur		ın Sun	
	Art Unit		1647	
	Examiner Name	DEBE	RRY, Regina M	
	Attorney Docket Numb	er	X-18530	

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines whe nt Passages or Rele s Appear	
	1									
If you wish to add additional S. Patent citation information please click the Add button.										
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No		Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1		DUPL	ICATE	1					
If you wisl	h to ad	d additional U.S. Puk	lished Ap	plication	citatio	n information p	lease click the Add	d button	Add	
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	5				Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	y F	Pages,Columns,Line vhere Relevant Passages or Relevar Figures Appear	_{T5}
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10575977		
Filing Date		2007-05-02		
First Named Inventor	Haijun Sun			
Art Unit		1647		
Examiner Name	DEBERRY, Regina M			
Attorney Docket Number		X-18530		

1	ABATH and SIMPSON, Peptide Research, 3(4):167-168 (1990)	
2	AUSUBEL et al., Current Protocols in Molecular Biology, 1:2.20.3, Green Publishing Associates, Inc., and John Wiley & Sons, Inc, New York (1989)	
3	BAYES et al., "Gateways To Clinical Trials." Methods and Findings in Experimental and Clinical Pharmacology, 25(6):483-506 at 491, Prous, Barcelona, Spain (July 2003)	
4	BLANCKAERT et al., "Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1. "Hybridoma and Hybridomics, 21(3): 153-159 (June 2002)	
5	BOERNER et al., J. Immunol, 147(1):86-95 (1991) DUPLICATE	
6	DIECKMANN and TZAGOLOFF, J. Biol. Chem., 260:1513-1520 (1935)	
7	FISHWILD et al., Nature Biotechnology, 14:845-51 (1996)	
8	SMITH, et al., Gene, 67:31-40 (1988)	
9	HOOGENBOOM and WINTER, J. Mol Biol., 227:381 (1991)	
10	JOHNSON et al., "The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain." Molecular and Cellular Biology, 11(9):4627-4634 (September 1991)	
11	KAUFMANN and SHARP, "Amplification and Expression of Sequences Cotransfected with A Modular Dihydorfolate Reductase Complementary DNA Gene." J. Mol. Biol., 159:601-621 (1982)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575977		
Filing Date		2007-05-02		
First Named Inventor	Haijur	Haijun Sun		
Art Unit		1647		
Examiner Name	DEBERRY, Regina M			
Attorney Docket Number		X-18530		

	8		
1	12	KOSTRZEWA et al., "Genomic structure and complete sequence of the human FGFR4 gene." Wammalian Genome: Official Journal of the International Mammalian Genome Society, 1(2):131-135 (February 1998)	
1	13	LONBERG and NUSZAR, Intern Rev. Immunol, 13:65-93 (1995)	
1	14	LONBERG et al., Nature, 3 8:856-859 (1994)	
1	15	MARKS et al., J. Mol. Biol., 222:581 (1991)	
1	16	MORRISON, Nature, 368:812-813 (1994) DUPLICATE	
1	17	NEUBERGER, Nature Biotechnology, 14:826 (1996)	
1	18	PARTRIDGE et al., "Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration." Journal of Cellular Biochemistry, 78(3):487-499 (June 6, 2000)	
1	19	POWERS et al., "Fibroblast growth factors, their receptors and signaling." Endocrine Related Cancer, 7:165-197 at 165-197 (2000)	
2	20	SKAPER et al., "The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects." Journal of Neurochemistry, 75(4):1520-1527 (October 2000)	
2	21	SOUTHERN and BERG, J. Mol. Appl. Genet., 1:327-341 (1982)	
2	22	STEGER et al., "Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium." Histochemistry and Cell Biology, 110(1):57-62, Germany (1998)	

Application Number 10575977 Filing Date 2007-05-02 INFORMATION DISCLOSURE First Named Inventor Haijun Sun STATEMENT BY APPLICANT Art Unit 1647 (Not for submission under 37 CFR 1.99) DEBERRY, Regina M **Examiner Name** Attorney Docket Number X-18530 SUN &al., "Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but 23 reversible hypophagia and weight loss in rodents and monkeys." American Journal of Physiolog Endocrinology and Metabolism, 292(3):E964-E976 (March 2007) 24 25 DUPLICATE 26 Add If you wish to add additional non-patent literature document citation information please click the Add button **EXAMINER SIGNATURE Date Considered Examiner Signature** *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that usued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.